1. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation 1979; 59: 1098-104. does not support the view, expressed be some,2 that amrinone's vasodilator properties may be due to "withdrawal of enhanced sympathetic constrictor tone consequent to improvement in ventricular per-;LeJemtel, T.H.; Keung, E.; Sonnenblick, E.H.
2. Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration;LeJemtel, T.H.; Keung, E.C.; Schwartz, W.J.;Trans Assoc Am Physicians,1979
3. Alousi formance." If, as we suspect, it is subsequently confirmed that amrinone does cause release of catecholamines and AA. Hemodynamic assessment of amrinone: a new inotropic agent;Benotti, JR, Grossman; W, Braunwald; E, Davolos; D.D.;N EnglJ Med,1978
4. Estudio de los efectos hemodinimicos de diferentes dosis de un nuevo in6tropico: la increase of circulating free fatty acids in some indiamrinona;Cardenas, L.M.; Vidaurri, D.A.;Arch Inst Cardiol Mex; viduals this may provide a mechanism for the increased incidence of ventricular arrhythmias and death in patients receiving amrinone reported by,1979
5. The clinical cardiovascular pharmacology of amrinone. A selective cardiotonic agent;Jennings, K.; Gwilt, D.; Crean, P.; Turnbull, S.; Gold, R.; Julian, D.G.;Acta Cardiol (Brux),1982